Foster PA - Search Results

1

Foster PA. Foster PA. Minerva Endocrinol. 2008 Mar;33(1):27-37. Minerva Endocrinol. 2008. PMID: 18277377 Free article. Review.

2

In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.

Foster PA, Newman SP, Chander SK, Stengel C, Jhalli R, Woo LL, Potter BV, Reed MJ, Purohit A. Foster PA, et al. Clin Cancer Res. 2006 Sep 15;12(18):5543-9. doi: 10.1158/1078-0432.CCR-06-0632. Clin Cancer Res. 2006. PMID: 17000691 Free article.

3

Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.

Foster PA, Chander SK, Parsons MF, Newman SP, Woo LW, Potter BV, Reed MJ, Purohit A. Foster PA, et al. Breast Cancer Res Treat. 2008 Sep;111(1):129-38. doi: 10.1007/s10549-007-9769-3. Epub 2007 Oct 4. Breast Cancer Res Treat. 2008. PMID: 17914670

4

2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique.

Foster PA, Ho YT, Newman SP, Kasprzyk PG, Leese MP, Potter BV, Reed MJ, Purohit A. Foster PA, et al. Breast Cancer Res Treat. 2008 Sep;111(2):251-60. doi: 10.1007/s10549-007-9791-5. Epub 2007 Oct 24. Breast Cancer Res Treat. 2008. PMID: 17957467

5

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers.

Newman SP, Foster PA, Ho YT, Day JM, Raobaikady B, Kasprzyk PG, Leese MP, Potter BV, Reed MJ, Purohit A. Newman SP, et al. Among authors: foster pa. Br J Cancer. 2007 Dec 17;97(12):1673-82. doi: 10.1038/sj.bjc.6604100. Epub 2007 Nov 20. Br J Cancer. 2007. PMID: 18026194 Free PMC article.

6

17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.

Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, Chander SK, Allan GM, Lawrence HR, Vicker N, Potter BV, Reed MJ, Purohit A. Day JM, et al. Among authors: foster pa. Int J Cancer. 2008 May 1;122(9):1931-40. doi: 10.1002/ijc.23350. Int J Cancer. 2008. PMID: 18183589

7

STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.

Newman SP, Foster PA, Stengel C, Day JM, Ho YT, Judde JG, Lassalle M, Prevost G, Leese MP, Potter BV, Reed MJ, Purohit A. Newman SP, et al. Among authors: foster pa. Clin Cancer Res. 2008 Jan 15;14(2):597-606. doi: 10.1158/1078-0432.CCR-07-1717. Clin Cancer Res. 2008. PMID: 18223236 Free article.

8

The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer.

Foster PA, Woo LW, Potter BV, Reed MJ, Purohit A. Foster PA, et al. Endocrinology. 2008 Aug;149(8):4035-42. doi: 10.1210/en.2008-0223. Epub 2008 May 1. Endocrinology. 2008. PMID: 18450955 Free PMC article.

9

A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer.

Foster PA, Newman SP, Leese MP, Bernetiere S, Diolez C, Camara J, Hacher B, Baronnet MM, Ali T, Potter BV, Reed MJ, Purohit A. Foster PA, et al. Anticancer Res. 2008 Mar-Apr;28(2A):577-81. Anticancer Res. 2008. PMID: 18506995 Free article.

10

Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.

Day JM, Tutill HJ, Foster PA, Bailey HV, Heaton WB, Sharland CM, Vicker N, Potter BV, Purohit A, Reed MJ. Day JM, et al. Among authors: foster pa. Mol Cell Endocrinol. 2009 Mar 25;301(1-2):251-8. doi: 10.1016/j.mce.2008.08.014. Epub 2008 Aug 22. Mol Cell Endocrinol. 2009. PMID: 18786604

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters